Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 14/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089961 | 0.91 | SOS1 (0.45) | PTGESPTGS2HRH3 | |
| SCHEMBL3101725 | 0.80 | HTR3E (0.55) | PTGESPTGS2 | |
| SCHEMBL3082150 | 0.76 | PTGES (0.53) | PTGESPTGS2 | |
| SCHEMBL29551098 | 0.75 | PTGES (0.61) | PTGESPTGS2 | |
| SCHEMBL24462181 | 0.75 | PTGES (0.61) | PTGESPTGS2 | |
| SCHEMBL29435909 | 0.75 | PTGES (0.56) | PTGESPTGS2 | |
| SCHEMBL13838771 | 0.75 | PTGES (0.56) | PTGESPTGS2 | |
| SCHEMBL17830179 | 0.75 | PTGES (0.56) | PTGESPTGS2 | |
| SCHEMBL13735326 | 0.75 | PTGES (0.56) | PTGESPTGS2 | |
| SCHEMBL13735931 | 0.75 | PTGES (0.56) | PTGESPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | PTGES 981/4885PTGS2 292/4885GABRP 3902/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | PTGES 981/4885PTGS2 292/4885GABRP 3902/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | PTGES 981/4885PTGS2 292/4885GABRP 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.